Sony Tuteja1, Henry Glick2, William Matthai3, Irving Nachamkin4, Ashwin Nathan3,5, Karen Monono1, Craig Carcuffe3, Karen Maslowski3, Gene Chang3, Taisei Kobayashi3,5, Saif Anwaruddin3, John Hirshfeld3, Robert L Wilensky3,5, Howard C Herrmann3, Daniel M Kolansky3, Daniel J Rader1,6, Jay Giri3,5. 1. Department of Medicine, Division of Translational Medicine and Human Genetics (S.T., K. Monono, D.J.R.), University of Pennsylvania Perelman School of Medicine, Philadelphia. 2. Department of Biostatistics and Epidemiology (H.G.), University of Pennsylvania Perelman School of Medicine, Philadelphia. 3. Cardiovascular Medicine Division (W.M., A.N., C.C., K. Maslowski, G.C., T.K., S.A., J.H., R.L.W., H.C.H., D.M.K., J.G.), University of Pennsylvania Perelman School of Medicine, Philadelphia. 4. Department of Pathology and Laboratory Medicine (I.N.), University of Pennsylvania Perelman School of Medicine, Philadelphia. 5. Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics (A.N., T.K., R.L.W., J.G.), University of Pennsylvania Perelman School of Medicine, Philadelphia. 6. Department of Genetics (D.J.R.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Abstract
BACKGROUND: CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after percutaneous coronary intervention, but the clinical impact of implementing CYP2C19 genotyping in a real-world setting is unknown. The purpose of the study was to determine whether returning CYP2C19 genotype results along with genotype-guided pharmacotherapy recommendations using a rapid turnaround test would change antiplatelet prescribing following percutaneous coronary intervention.The primary outcome was the rate of prasugrel or ticagrelor prescribing in each arm. Secondary outcomes included agreement to the genotype-guided recommendations. METHODS: At the time of percutaneous coronary intervention, participants were randomly assigned to prospective rapid point-of-care genotyping of CYP2C19 major alleles (*2, *3, *17) via salivary swab (genotyped group) or no genotyping (usual care) to guide antiplatelet drug selection. Interventional cardiologists at 2 cardiac catheterization laboratories within the same health system were provided genotype information along with genotype-guided pharmacotherapy recommendations. RESULTS: A total of 504 participants were randomized, 249 to the genotyped and 255 to the usual care group. The participants were primarily men (73%); age, 63±10 years; and 50% had acute coronary syndromes. In the genotyped group, 28% were carriers of loss-of-function alleles (*2, *3). The use of prasugrel or ticagrelor was significantly higher in the genotyped group compared with the usual care group (30% versus 21%; odds ratio, 1.60 [95% CI, 1.07-2.42]; P=0.03). Within the genotyped group, 53% of loss-of-function allele carriers were started on prasugrel/ticagrelor, while 47% were started on clopidogrel. CONCLUSIONS: In a randomized controlled trial of clinical CYP2C19 genotyping implementation, pharmacogenetic test results significantly influenced antiplatelet drug prescribing; however, almost half of CYP2C19 loss-of-function carriers continued to receive clopidogrel. Interventional cardiologists consider both clinical and genetic factors when selecting antiplatelet therapy following percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT02508116.
RCT Entities:
BACKGROUND:CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after percutaneous coronary intervention, but the clinical impact of implementing CYP2C19 genotyping in a real-world setting is unknown. The purpose of the study was to determine whether returning CYP2C19 genotype results along with genotype-guided pharmacotherapy recommendations using a rapid turnaround test would change antiplatelet prescribing following percutaneous coronary intervention.The primary outcome was the rate of prasugrel or ticagrelor prescribing in each arm. Secondary outcomes included agreement to the genotype-guided recommendations. METHODS: At the time of percutaneous coronary intervention, participants were randomly assigned to prospective rapid point-of-care genotyping of CYP2C19 major alleles (*2, *3, *17) via salivary swab (genotyped group) or no genotyping (usual care) to guide antiplatelet drug selection. Interventional cardiologists at 2 cardiac catheterization laboratories within the same health system were provided genotype information along with genotype-guided pharmacotherapy recommendations. RESULTS: A total of 504 participants were randomized, 249 to the genotyped and 255 to the usual care group. The participants were primarily men (73%); age, 63±10 years; and 50% had acute coronary syndromes. In the genotyped group, 28% were carriers of loss-of-function alleles (*2, *3). The use of prasugrel or ticagrelor was significantly higher in the genotyped group compared with the usual care group (30% versus 21%; odds ratio, 1.60 [95% CI, 1.07-2.42]; P=0.03). Within the genotyped group, 53% of loss-of-function allele carriers were started on prasugrel/ticagrelor, while 47% were started on clopidogrel. CONCLUSIONS: In a randomized controlled trial of clinical CYP2C19 genotyping implementation, pharmacogenetic test results significantly influenced antiplatelet drug prescribing; however, almost half of CYP2C19 loss-of-function carriers continued to receive clopidogrel. Interventional cardiologists consider both clinical and genetic factors when selecting antiplatelet therapy following percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT02508116.
Entities:
Keywords:
clinical trial; clopidogrel; humans; pharmacogenetics; precision medicine
Authors: Grace Lee; Lisa A Varughese; Laura Conway; Carol Stojinski; Sandhya Ashokkumar; Karen Monono; William Matthai; Daniel M Kolansky; Jay Giri; Sony Tuteja Journal: Per Med Date: 2022-01-05 Impact factor: 2.512
Authors: Vibhu Parcha; Brittain F Heindl; Peng Li; Rajat Kalra; Nita A Limdi; Naveen L Pereira; Garima Arora; Pankaj Arora Journal: Circ Genom Precis Med Date: 2021-10-21
Authors: Catherine Hajek; Allison M Hutchinson; Lauren N Galbraith; Robert C Green; Michael F Murray; Natasha Petry; Charlene L Preys; Carrie L B Zawatsky; Emilie S Zoltick; Kurt D Christensen Journal: Genet Med Date: 2021-11-30 Impact factor: 8.864
Authors: Abdullah Al-Abcha; Yasser Radwan; Danielle Blais; Ernest L Mazzaferri; Konstantinos Dean Boudoulas; Essa M Essa; Richard J Gumina Journal: Front Cardiovasc Med Date: 2022-03-23
Authors: Craig R Lee; Cameron D Thomas; Amber L Beitelshees; Sony Tuteja; Philip E Empey; James C Lee; Nita A Limdi; Julio D Duarte; Todd C Skaar; Yiqing Chen; Kelsey J Cook; James C Coons; Chrisly Dillon; Francesco Franchi; Jay Giri; Yan Gong; Rolf P Kreutz; Caitrin W McDonough; James M Stevenson; Karen E Weck; Dominick J Angiolillo; Julie A Johnson; George A Stouffer; Larisa H Cavallari Journal: Clin Pharmacol Ther Date: 2020-10-02 Impact factor: 6.875